person · Reporting owner

ORDAN MARK S

Disclosed activity across 6 companies

Tapewire entity: 42006
SEC CIK: 0001208541

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Carlyle Group Inc.CG · Entity 3316	Director	May 01, 2026	May 01, 2026
FEDERAL REALTY INVESTMENT TRUSTFRT · Entity 3517	Director	January 03, 2022	January 04, 2022
Pediatrix Medical Group, Inc.MD · Entity 4451	Director · Chief Executive Officer	June 01, 2026	June 03, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Carlyle Group Inc.

Report date May 01, 2026 · Filed May 01, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	30,613	Ending reported balance After 2026-05-01 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2026-05-01 · Grant · Acquired 4,450 · Balance 26,163 F1: These securities are a restricted stock unit award granted under The Carlyle Group Inc. Amended & Restated 2012 Equity Incentive Plan. These securities will vest on May 1, 2027, subject to the reporting person's continued service on the Board of Directors of The Carlyle Group Inc. on such vesting date. Row 2 · 2026-05-01 · Grant · Acquired 4,450 · Balance 30,613 F2: These securities are shares of the Issuer's common stock granted under The Carlyle Group Inc. Amended & Restated 2012 Equity Incentive Plan. These securities are vested upon grant pursuant to an election made by the reporting person to receive shares of the Issuer's common stock in lieu of the reporting person's annual cash retainers for service on the Issuer's Board of Directors.

Filing footnotes · ownership attribution and instrument terms

F1: These securities are a restricted stock unit award granted under The Carlyle Group Inc. Amended & Restated 2012 Equity Incentive Plan. These securities will vest on May 1, 2027, subject to the reporting person's continued service on the Board of Directors of The Carlyle Group Inc. on such vesting date.

F2: These securities are shares of the Issuer's common stock granted under The Carlyle Group Inc. Amended & Restated 2012 Equity Incentive Plan. These securities are vested upon grant pursuant to an election made by the reporting person to receive shares of the Issuer's common stock in lieu of the reporting person's annual cash retainers for service on the Issuer's Board of Directors.

FEDERAL REALTY INVESTMENT TRUST

Report date January 03, 2022 · Filed January 04, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Shares of Beneficial InterestSEC Table I · non-derivative	Direct	3,102	Reported balance After 2022-01-03 transaction · row 1 1 source row Row 1 · 2022-01-03 · Grant · Acquired 880 · Balance 3,102

Pediatrix Medical Group, Inc.

Report date June 01, 2026 · Filed June 03, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	410,884	Ending reported balance After 2026-06-02 transaction · row 4 4 source rows · reconciled sequence Row 1 · 2026-06-01 · Grant · Acquired 127,198 · Balance 430,003 F1: Restricted shares granted pursuant to the Issuer's Second Amended and Restated 2008 Incentive Compensation Plan (the "Plan"), in connection with an annual equity award. Twenty-five percent (25%) of the restricted shares will vest on June 1, 2027, twenty-five percent (25%) of the restricted shares will vest on June 1, 2028 and fifty percent (50%) of the restricted shares will vest on June 1, 2029, subject to the terms of the Plan. Row 2 · 2026-06-01 · Tax withholding · Disposed 19,119 · Balance 410,884 F2: Represents 19,119 restricted shares withheld for payment of taxes upon vesting of shares. Row 3 · 2026-06-02 · Disposition to issuer · Disposed 97,174 · Balance 313,710 F3: The Reporting Person filed a Form 4 on June 3, 2025, reporting an annual equity award of 194,347 restricted shares granted on June 1, 2025 pursuant to the Issuer's Amended and Restated 2008 Incentive Compensation Plan (as further amended and restated on May 7, 2026, the "Plan"), which award, as originally reported, vested as to twenty-five percent (25%) on June 1, 2026, with the remaining portion scheduled to vest twenty-five percent (25%) on June 1, 2027 and fifty percent (50%) on June 1, 2028, in each case subject to the terms of the Plan. Due to the annual award limitations of the Plan, the award was revised so that the remaining fifty percent (50%) of the award that was scheduled to vest on June 1, 2028 was re-granted on June 2, 2026, which portion will still vest on June 1, 2028 in accordance with the original terms of the award, subject to the terms of the Plan and the underlying award agreement. Row 4 · 2026-06-02 · Grant · Acquired 97,174 · Balance 410,884 F3: The Reporting Person filed a Form 4 on June 3, 2025, reporting an annual equity award of 194,347 restricted shares granted on June 1, 2025 pursuant to the Issuer's Amended and Restated 2008 Incentive Compensation Plan (as further amended and restated on May 7, 2026, the "Plan"), which award, as originally reported, vested as to twenty-five percent (25%) on June 1, 2026, with the remaining portion scheduled to vest twenty-five percent (25%) on June 1, 2027 and fifty percent (50%) on June 1, 2028, in each case subject to the terms of the Plan. Due to the annual award limitations of the Plan, the award was revised so that the remaining fifty percent (50%) of the award that was scheduled to vest on June 1, 2028 was re-granted on June 2, 2026, which portion will still vest on June 1, 2028 in accordance with the original terms of the award, subject to the terms of the Plan and the underlying award agreement.

Filing footnotes · ownership attribution and instrument terms

F1: Restricted shares granted pursuant to the Issuer's Second Amended and Restated 2008 Incentive Compensation Plan (the "Plan"), in connection with an annual equity award. Twenty-five percent (25%) of the restricted shares will vest on June 1, 2027, twenty-five percent (25%) of the restricted shares will vest on June 1, 2028 and fifty percent (50%) of the restricted shares will vest on June 1, 2029, subject to the terms of the Plan.

F2: Represents 19,119 restricted shares withheld for payment of taxes upon vesting of shares.

F3: The Reporting Person filed a Form 4 on June 3, 2025, reporting an annual equity award of 194,347 restricted shares granted on June 1, 2025 pursuant to the Issuer's Amended and Restated 2008 Incentive Compensation Plan (as further amended and restated on May 7, 2026, the "Plan"), which award, as originally reported, vested as to twenty-five percent (25%) on June 1, 2026, with the remaining portion scheduled to vest twenty-five percent (25%) on June 1, 2027 and fifty percent (50%) on June 1, 2028, in each case subject to the terms of the Plan. Due to the annual award limitations of the Plan, the award was revised so that the remaining fifty percent (50%) of the award that was scheduled to vest on June 1, 2028 was re-granted on June 2, 2026, which portion will still vest on June 1, 2028 in accordance with the original terms of the award, subject to the terms of the Plan and the underlying award agreement.

Past disclosures · reporting ended (3)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Forest City Realty Trust, Inc.

Report date December 07, 2018 · Filed December 07, 2018

Section 16 reporting ended · disclosed 2018-12-07. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2018-12-07 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2018-12-07 · Disposition to issuer · Disposed 5,432 · Balance 0 F2: Pursuant to a Merger Agreement dated 7/30/2018, among issuer, Antlia Holdings, LLC and Antlia Merger Sub Inc. (the "Merger Agreement"), at the effective time of the Merger, as contemplated in the Merger Agreement (the "Effective Time"), the restricted shares, outstanding immediately prior to the Effective Time automatically vested and entitled the holder to receive a cash payment of $25.35 per share (the "Merger Consideration") without interest and less any applicable tax withholdings. F1: Restricted Stock Grant pursuant to Forest City Realty Trust, Inc. 1994 Stock Plan - 100% vest on 6/20/2019.

Filing footnotes · ownership attribution and instrument terms

F1: Restricted Stock Grant pursuant to Forest City Realty Trust, Inc. 1994 Stock Plan - 100% vest on 6/20/2019.

F2: Pursuant to a Merger Agreement dated 7/30/2018, among issuer, Antlia Holdings, LLC and Antlia Merger Sub Inc. (the "Merger Agreement"), at the effective time of the Merger, as contemplated in the Merger Agreement (the "Effective Time"), the restricted shares, outstanding immediately prior to the Effective Time automatically vested and entitled the holder to receive a cash payment of $25.35 per share (the "Merger Consideration") without interest and less any applicable tax withholdings.

QUALITY CARE PROPERTIES, INC.

Report date July 17, 2018 · Filed July 27, 2018

Section 16 reporting ended · disclosed 2018-07-27. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2018-07-17 transaction · row 1 Sequence does not reconcile; account continuity is unresolved. 1 source row Row 1 · 2018-07-17 · Gift · Disposed 18,551 · Balance 0 F1: This transaction reflects Mr. Ordan's gift to Vassar College.
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2018-07-26 transaction · row 2 Sequence does not reconcile; account continuity is unresolved. 1 source row Row 2 · 2018-07-26 · Disposition to issuer · Disposed 280,529 · Balance 0 F2: Upon the July 26, 2018 closing of the merger (the "Merger") of Quality Care Properties, Inc. ("QCP") with and into Welltower Inc. ("Welltower") in which Welltower acquired all of the outstanding capital stock of QCP, each outstanding QCP restricted stock award fully vested and was converted into the right to receive $20.75 in respect of each share subject to the restricted stock award, with the number of shares in respect of awards subject to performance-based vesting conditions determined assuming performance goals were fully satisfied.
Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.73 · Expires 2023-12-15	Direct	Reported balance After 2018-07-26 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2018-07-26 · Disposition to issuer · Disposed 1,594,694 · Balance 0 F3: Each stock option represents the right to buy, upon exercise, one share of common stock of QCP. F4: Upon the closing of the Merger, each outstanding QCP option subject to service-based vesting fully vested and was converted into the right to receive, for each share underlying the option, $20.75 less the applicable exercise price of the option. Upon the closing of the Merger, each outstanding QCP option subject to performance-based vesting conditions vested to the extent the applicable stock price hurdle relating to such option was met in connection with the transaction, and was converted into the right to receive, for each share underlying the option, $20.75 less the applicable exercise price of the option.
Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.73 · Expires 2023-12-15	Direct	Reported balance After 2018-07-26 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2018-07-26 · Disposition to issuer · Disposed 600,000 · Balance 0 F3: Each stock option represents the right to buy, upon exercise, one share of common stock of QCP. F5: These QCP options did not vest and were forfeited because the applicable stock price hurdle relating to such option was not met in connection with the Merger.
Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2019-11-29	Direct	Reported balance After 2018-07-26 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2018-07-26 · Disposition to issuer · Disposed 203,804 · Balance 0 F6: Each restricted stock unit represents the right to receive, at settlement, one share of common stock of QCP. F7: Upon the closing of the Merger, each outstanding QCP restricted stock unit award fully vested and was converted into the right to receive $20.75 in respect of each share underlying the restricted stock unit award.

Filing footnotes · ownership attribution and instrument terms

F1: This transaction reflects Mr. Ordan's gift to Vassar College.

F2: Upon the July 26, 2018 closing of the merger (the "Merger") of Quality Care Properties, Inc. ("QCP") with and into Welltower Inc. ("Welltower") in which Welltower acquired all of the outstanding capital stock of QCP, each outstanding QCP restricted stock award fully vested and was converted into the right to receive $20.75 in respect of each share subject to the restricted stock award, with the number of shares in respect of awards subject to performance-based vesting conditions determined assuming performance goals were fully satisfied.

F3: Each stock option represents the right to buy, upon exercise, one share of common stock of QCP.

F4: Upon the closing of the Merger, each outstanding QCP option subject to service-based vesting fully vested and was converted into the right to receive, for each share underlying the option, $20.75 less the applicable exercise price of the option. Upon the closing of the Merger, each outstanding QCP option subject to performance-based vesting conditions vested to the extent the applicable stock price hurdle relating to such option was met in connection with the transaction, and was converted into the right to receive, for each share underlying the option, $20.75 less the applicable exercise price of the option.

F5: These QCP options did not vest and were forfeited because the applicable stock price hurdle relating to such option was not met in connection with the Merger.

F6: Each restricted stock unit represents the right to receive, at settlement, one share of common stock of QCP.

F7: Upon the closing of the Merger, each outstanding QCP restricted stock unit award fully vested and was converted into the right to receive $20.75 in respect of each share underlying the restricted stock unit award.

VEREIT, Inc.

Report date July 13, 2020 · Filed July 14, 2020

Section 16 reporting ended · disclosed 2020-07-14. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	131,206	Ending reported balance After 2020-07-13 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2020-07-13 · Grant · Acquired 544 · Balance 130,095 F1: Reflects deferred stock units granted on July 13, 2020, in lieu of director fees pursuant to the director's deferral election. Such deferred stock units will be settled in common stock in connection with the Reporting Person's separation of service from the Issuer. F2: Reflects the closing sale price of the Issuer's common stock as reported on the New York Stock Exchange on July 13, 2020. Row 2 · 2020-07-13 · Grant · Acquired 1,111 · Balance 131,206 F3: Reflects deferred stock units granted on July 13, 2020 in lieu of dividends pursuant to the director's deferral election. Such deferred stock units will be settled in common stock in connection with the Reporting Person's separation of service from the Issuer. F4: Reflects the average of the closing sale price as reported on the New York Stock Exchange on January 15, 2020 and April 15, 2020.

Filing footnotes · ownership attribution and instrument terms

F1: Reflects deferred stock units granted on July 13, 2020, in lieu of director fees pursuant to the director's deferral election. Such deferred stock units will be settled in common stock in connection with the Reporting Person's separation of service from the Issuer.

F2: Reflects the closing sale price of the Issuer's common stock as reported on the New York Stock Exchange on July 13, 2020.

F3: Reflects deferred stock units granted on July 13, 2020 in lieu of dividends pursuant to the director's deferral election. Such deferred stock units will be settled in common stock in connection with the Reporting Person's separation of service from the Issuer.

F4: Reflects the average of the closing sale price as reported on the New York Stock Exchange on January 15, 2020 and April 15, 2020.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 02, 2026 Filed Jun 3, 2026 21:00 UTC	Pediatrix Medical Group, Inc. MD · Entity 4451	GrantCommon Stock	97,174	$0.00	$0.00	Disclosure SEC source: 0001193125-26-255705 · ownership.xml · nonDerivative · entry 4 ORDAN MARK S · CIK 0001208541 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 410,884 F3 · kind: The Reporting Person filed a Form 4 on June 3, 2025, reporting an annual equity award of 194,347 restricted shares granted on June 1, 2025 pursuant to the Issuer's Amended and Restated 2008 Incentive Compensation Plan (as further amended and restated on May 7, 2026, the "Plan"), which award, as originally reported, vested as to twenty-five percent (25%) on June 1, 2026, with the remaining portion scheduled to vest twenty-five percent (25%) on June 1, 2027 and fifty percent (50%) on June 1, 2028, in each case subject to the terms of the Plan. Due to the annual award limitations of the Plan, the award was revised so that the remaining fifty percent (50%) of the award that was scheduled to vest on June 1, 2028 was re-granted on June 2, 2026, which portion will still vest on June 1, 2028 in accordance with the original terms of the award, subject to the terms of the Plan and the underlying award agreement. Read SEC document
June 02, 2026 Filed Jun 3, 2026 21:00 UTC	Pediatrix Medical Group, Inc. MD · Entity 4451	Disposition to issuerCommon Stock	97,174	$0.00	$0.00	Disclosure SEC source: 0001193125-26-255705 · ownership.xml · nonDerivative · entry 3 ORDAN MARK S · CIK 0001208541 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 313,710 F3 · kind: The Reporting Person filed a Form 4 on June 3, 2025, reporting an annual equity award of 194,347 restricted shares granted on June 1, 2025 pursuant to the Issuer's Amended and Restated 2008 Incentive Compensation Plan (as further amended and restated on May 7, 2026, the "Plan"), which award, as originally reported, vested as to twenty-five percent (25%) on June 1, 2026, with the remaining portion scheduled to vest twenty-five percent (25%) on June 1, 2027 and fifty percent (50%) on June 1, 2028, in each case subject to the terms of the Plan. Due to the annual award limitations of the Plan, the award was revised so that the remaining fifty percent (50%) of the award that was scheduled to vest on June 1, 2028 was re-granted on June 2, 2026, which portion will still vest on June 1, 2028 in accordance with the original terms of the award, subject to the terms of the Plan and the underlying award agreement. Read SEC document
June 01, 2026 Filed Jun 3, 2026 21:00 UTC	Pediatrix Medical Group, Inc. MD · Entity 4451	Tax withholdingCommon Stock	19,119	$21.54	$411,823.26	Disclosure SEC source: 0001193125-26-255705 · ownership.xml · nonDerivative · entry 2 ORDAN MARK S · CIK 0001208541 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 410,884 F2 · kind: Represents 19,119 restricted shares withheld for payment of taxes upon vesting of shares. Read SEC document
June 01, 2026 Filed Jun 3, 2026 21:00 UTC	Pediatrix Medical Group, Inc. MD · Entity 4451	GrantCommon Stock	127,198	$0.00	$0.00	Disclosure SEC source: 0001193125-26-255705 · ownership.xml · nonDerivative · entry 1 ORDAN MARK S · CIK 0001208541 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 430,003 F1 · kind: Restricted shares granted pursuant to the Issuer's Second Amended and Restated 2008 Incentive Compensation Plan (the "Plan"), in connection with an annual equity award. Twenty-five percent (25%) of the restricted shares will vest on June 1, 2027, twenty-five percent (25%) of the restricted shares will vest on June 1, 2028 and fifty percent (50%) of the restricted shares will vest on June 1, 2029, subject to the terms of the Plan. Read SEC document
May 01, 2026 Filed May 1, 2026 22:27 UTC	Carlyle Group Inc. CG · Entity 3316	GrantCommon Stock	4,450	$49.44	$220,008.00	Disclosure SEC source: 0001628280-26-029468 · wk-form4_1777674462.xml · nonDerivative · entry 2 ORDAN MARK S · CIK 0001208541 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,613 F2 · kind: These securities are shares of the Issuer's common stock granted under The Carlyle Group Inc. Amended & Restated 2012 Equity Incentive Plan. These securities are vested upon grant pursuant to an election made by the reporting person to receive shares of the Issuer's common stock in lieu of the reporting person's annual cash retainers for service on the Issuer's Board of Directors. Read SEC document
May 01, 2026 Filed May 1, 2026 22:27 UTC	Carlyle Group Inc. CG · Entity 3316	GrantCommon Stock	4,450	$0.00	$0.00	Disclosure SEC source: 0001628280-26-029468 · wk-form4_1777674462.xml · nonDerivative · entry 1 ORDAN MARK S · CIK 0001208541 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,163 F1 · kind: These securities are a restricted stock unit award granted under The Carlyle Group Inc. Amended & Restated 2012 Equity Incentive Plan. These securities will vest on May 1, 2027, subject to the reporting person's continued service on the Board of Directors of The Carlyle Group Inc. on such vesting date. Read SEC document
December 15, 2025 Filed Dec 17, 2025 22:00 UTC	Pediatrix Medical Group, Inc. MD · Entity 4451	SaleCommon Stock	23,000	$22.41	$515,430.00	Disclosure SEC source: 0001193125-25-322897 · ownership.xml · nonDerivative · entry 1 ORDAN MARK S · CIK 0001208541 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 302,805 F1 · price: The price in Colum 4 is a weighted average price. The reported securities were sold in multiple transactions with prices ranging from $22.00 to $22.62 for a weighted average sales price of $22.41. The reporting person undertakes to provide the issuer, any security holder of the issuer of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each seperate price within the range set forth in this footnote. Read SEC document
June 01, 2025 Filed Jun 3, 2025 21:00 UTC	Pediatrix Medical Group, Inc. MD · Entity 4451	GrantCommon Stock	194,347	$0.00	$0.00	Disclosure SEC source: 0000950170-25-081078 · ownership.xml · nonDerivative · entry 1 ORDAN MARK S · CIK 0001208541 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 325,805 F1 · kind: Restricted shares granted pursuant to the Issuer's Amended and Restated 2008 Incentive Compensation Plan (the "Plan"), in connection with an annual equity award. Twenty-five percent (25%) of the restricted shares will vest on June 1, 2026, twenty-five percent (25%) of the restricted shares will vest on June 1, 2027 and fifty percent (50%) of the restricted shares will vest on June 1, 2028, subject to the terms of the Plan. Read SEC document
May 09, 2025 Filed May 12, 2025 21:00 UTC	Pediatrix Medical Group, Inc. MD · Entity 4451	Tax withholdingCommon Stock	7,225	$14.44	$104,329.00	Disclosure SEC source: 0000950170-25-069428 · ownership.xml · nonDerivative · entry 1 ORDAN MARK S · CIK 0001208541 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 131,458 F1 · kind: Represents 7,225 restricted shares withheld for payment of taxes upon vesting of shares. Read SEC document
May 01, 2025 Filed May 2, 2025 20:25 UTC	Carlyle Group Inc. CG · Entity 3316	GrantCommon Stock	5,235	$0.00	$0.00	Disclosure SEC source: 0001527166-25-000060 · wk-form4_1746217511.xml · nonDerivative · entry 1 ORDAN MARK S · CIK 0001208541 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,713 F1 · kind: These securities are a restricted stock unit award granted under The Carlyle Group Inc. Amended & Restated 2012 Equity Incentive Plan. These securities will vest on May 1, 2026, subject to the reporting person's continued service on the Board of Directors of The Carlyle Group Inc. on such vesting date. Read SEC document
January 12, 2025 Filed Jan 14, 2025 22:30 UTC	Pediatrix Medical Group, Inc. MD · Entity 4451	GrantPerformance Share Unit · Derivative	640,000	$0.00	$0.00	Disclosure SEC source: 0000950170-25-005487 · ownership.xml · derivative · entry 1 ORDAN MARK S · CIK 0001208541 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 640,000 Underlying: Common Stock · 640,000 shares Expires not disclosed F1 · derivative.exercise_price: Each Performance Share Unit ("PSU") represents a contingent right to receive one share of the Issuer's Common Stock upon vesting. The PSUs vest upon the satisfaction of both a service-based condition and a performance-based condition. The PSUs will vest, to the extent earned, on the three-year anniversary of the grant date, with the shares underlying the PSUs being earned in one-third installments based on the Issuer achieving stock price hurdles equal to 125%, 150% and 175% of $13.55 for at least 20 consecutive trading days before the third anniversary of the grant date. F1 · derivative.exercise_date: Each Performance Share Unit ("PSU") represents a contingent right to receive one share of the Issuer's Common Stock upon vesting. The PSUs vest upon the satisfaction of both a service-based condition and a performance-based condition. The PSUs will vest, to the extent earned, on the three-year anniversary of the grant date, with the shares underlying the PSUs being earned in one-third installments based on the Issuer achieving stock price hurdles equal to 125%, 150% and 175% of $13.55 for at least 20 consecutive trading days before the third anniversary of the grant date. F1 · derivative.expiration_date: Each Performance Share Unit ("PSU") represents a contingent right to receive one share of the Issuer's Common Stock upon vesting. The PSUs vest upon the satisfaction of both a service-based condition and a performance-based condition. The PSUs will vest, to the extent earned, on the three-year anniversary of the grant date, with the shares underlying the PSUs being earned in one-third installments based on the Issuer achieving stock price hurdles equal to 125%, 150% and 175% of $13.55 for at least 20 consecutive trading days before the third anniversary of the grant date. Read SEC document
November 13, 2024 Filed Nov 14, 2024 22:00 UTC	Pediatrix Medical Group, Inc. MD · Entity 4451	SaleCommon Stock	27,600	$15.35	$423,660.00	Disclosure SEC source: 0000950170-24-127164 · ownership.xml · nonDerivative · entry 1 ORDAN MARK S · CIK 0001208541 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 138,683 F1 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions with prices ranging from $15.17 to $15.52 for a weighted average sales price of $15.35. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each seperate price within the range set forth in this footnote. Read SEC document
May 09, 2024 Filed May 13, 2024 21:00 UTC	Pediatrix Medical Group, Inc. MD · Entity 4451	GrantCommon Stock	18,360	$0.00	$0.00	Disclosure SEC source: 0000950170-24-058783 · ownership.xml · nonDerivative · entry 1 ORDAN MARK S · CIK 0001208541 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 166,283 F1 · kind: Restricted shares granted pursupant to Issuer's Amended and Restated 2008 Incentive Compensation Plan, in connection with annual equity award. Shares will vest on May 9, 2025. Read SEC document
May 01, 2024 Filed May 3, 2024 21:17 UTC	Carlyle Group Inc. CG · Entity 3316	GrantCommon Stock	5,004	$0.00	$0.00	Disclosure SEC source: 0000950170-24-053049 · ownership.xml · nonDerivative · entry 1 ORDAN MARK S · CIK 0001208541 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,478 F1 · shares: These securities are restricted stock unit awards granted under The Carlyle Group Inc. Amended & Restated 2012 Equity Incentive Plan. These securities will vest on May 1, 2025, subject to the reporting person's continued service on the Board of Directors of The Carlyle Group Inc. on such vesting date. Read SEC document
May 25, 2023 Filed May 26, 2023 21:00 UTC	Pediatrix Medical Group, Inc. MD · Entity 4451	SaleCommon Stock	33,000	$13.26	$437,580.00	Disclosure SEC source: 0001209191-23-032592 · doc4.xml · nonDerivative · entry 1 ORDAN MARK S · CIK 0001208541 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 147,923 F1 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions with prices ranging from $13.16 to $13.33 for a weighted average sales price of $13.26. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
May 11, 2023 Filed May 15, 2023 21:00 UTC	Pediatrix Medical Group, Inc. MD · Entity 4451	GrantCommon Stock	9,463	$0.00	$0.00	Disclosure SEC source: 0001209191-23-029512 · doc4.xml · nonDerivative · entry 1 ORDAN MARK S · CIK 0001208541 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 180,923 F1 · kind: Restricted shares granted pursuant to Issuer's Amended and Restated 2008 Incentive Compensation Plan (the "Plan"), in connection with annual equity award. Shares will vest on May 11, 2024. F2 · balance_after: Excludes 76,253 previously reported shares of restricted common stock granted to the reporting person pursuant to the Plan in connection with an annual equity award that were forfeited because the performance-based criteria were not achieved. Read SEC document
May 01, 2023 Filed May 3, 2023 21:05 UTC	Carlyle Group Inc. CG · Entity 3316	GrantCommon Stock	6,238	$0.00	$0.00	Disclosure SEC source: 0000899243-23-012101 · doc4.xml · nonDerivative · entry 1 ORDAN MARK S · CIK 0001208541 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,474 F1 · shares: These securities are restricted stock unit awards granted under The Carlyle Group Inc. Amended & Restated 2012 Equity Incentive Plan. These securities will vest on May 1, 2024, subject to the reporting person's continued service on the Board of Directors of The Carlyle Group Inc. on such vesting date. Read SEC document
December 31, 2022 Filed Jan 4, 2023 22:00 UTC	Pediatrix Medical Group, Inc. MD · Entity 4451	Tax withholdingCommon Stock	98,932	$14.86	$1,470,129.52	Disclosure SEC source: 0001209191-23-001044 · doc4.xml · nonDerivative · entry 1 ORDAN MARK S · CIK 0001208541 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 247,713 F1 · shares: Represents shares withheld for payment of taxes upon the accelerated vesting of shares of restricted stock in connection with the reporting person's termination without "Cause." Read SEC document
November 21, 2022 Filed Nov 23, 2022 22:00 UTC	Pediatrix Medical Group, Inc. MD · Entity 4451	SaleCommon Stock	22,166	$15.45	$342,464.70	Disclosure SEC source: 0001209191-22-058674 · doc4.xml · nonDerivative · entry 1 ORDAN MARK S · CIK 0001208541 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 346,645 F1 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions with prices ranging from $15.22 to $15.89 for a weighted average sales price of $15.45. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
May 01, 2022 Filed May 2, 2022 22:10 UTC	Carlyle Group Inc. CG · Entity 3316	GrantCommon Stock	5,236	$0.00	$0.00	Disclosure SEC source: 0000899243-22-016149 · doc4.xml · nonDerivative · entry 1 ORDAN MARK S · CIK 0001208541 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,236 F1 · shares: These securities are restricted stock unit awards granted under The Carlyle Group Inc. Amended & Restated 2012 Equity Incentive Plan. These securities will vest on May 1, 2023, subject to the reporting person's continued service on the Board of Directors of The Carlyle Group Inc. on such vesting date. Read SEC document
March 01, 2022 Filed Mar 3, 2022 22:00 UTC	Pediatrix Medical Group, Inc. MD · Entity 4451	Tax withholdingCommon Stock	20,691	$23.47	$485,617.77	Disclosure SEC source: 0001209191-22-015588 · doc4.xml · nonDerivative · entry 3 ORDAN MARK S · CIK 0001208541 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 368,811 F4 · kind: Represents 20,691 restricted shares withheld for payment of taxes upon vesting of shares. Read SEC document
March 01, 2022 Filed Mar 3, 2022 22:00 UTC	Pediatrix Medical Group, Inc. MD · Entity 4451	GrantCommon Stock	76,253	$0.00	$0.00	Disclosure SEC source: 0001209191-22-015588 · doc4.xml · nonDerivative · entry 2 ORDAN MARK S · CIK 0001208541 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 389,502 F3 · kind: Restricted shares granted pursuant to the Plan in connection with an annual equity award. The number of shares being reported represents the "target" number of restricted shares and does not include the right of the reporting person to receive up to 38,127 additional shares based on the achievement of certain performance-based criteria for the twelve months ending December 31, 2022. The actual number of shares earned could be less than or greater than the target number, depending on the level of performance achieved, and all of the restricted shares granted are subject to forfeiture if minimum levels of performance are not met. Any restricted shares earned will not vest any earlier than in three installments of twenty-five percent (25%) on March 1, 2023, twenty-five percent (25%) on March 1, 2024 and fifty percent (50%) on March 1, 2025, subject to the terms of the Plan. Read SEC document
March 01, 2022 Filed Mar 3, 2022 22:00 UTC	Pediatrix Medical Group, Inc. MD · Entity 4451	GrantCommon Stock	76,253	$0.00	$0.00	Disclosure SEC source: 0001209191-22-015588 · doc4.xml · nonDerivative · entry 1 ORDAN MARK S · CIK 0001208541 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 313,249 F1 · kind: Restricted shares granted pursuant to the Issuer's Amended and Restated 2008 Incentive Compensation Plan (the "Plan"), in connection with an annual equity award. Twenty-five percent (25%) of the restricted shares will vest on March 1, 2023, twenty-five percent (25%) of the restricted shares will vest on March 1, 2024 and fifty percent (50%) of the restricted shares will vest on March 1, 2025, subject to the terms of the Plan. F2 · balance_after: Includes 28,571 restricted shares granted pursuant to the Plan in connection with achievement in excess of target of specified performance-based criteria for the performance period from January 1, 2021 through December 31, 2021. Read SEC document
January 03, 2022 Filed Jan 4, 2022 22:49 UTC	FEDERAL REALTY INVESTMENT TRUST FRT · Entity 3517	GrantCommon Shares of Beneficial Interest	880	$0.00	$0.00	Disclosure SEC source: 0000034903-22-000002 · wf-form4_164133658282294.xml · nonDerivative · entry 1 ORDAN MARK S · CIK 0001208541 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,102 Read SEC document
August 30, 2021 Filed Aug 31, 2021 23:49 UTC	Pediatrix Medical Group, Inc. MD · Entity 4451	Exercise / conversionEmployee Stock Option (right to buy) · Derivative	95,000	$17.65 Strike: $17.65	$1,676,750.00	Disclosure SEC source: 0001209191-21-054168 · doc4.xml · derivative · entry 3 ORDAN MARK S · CIK 0001208541 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 455,331 Underlying: Common Stock · 95,000 shares Expires 2023-10-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Option to purchase shares of common stock granted on July 12, 2020 ("Grant Date") under the Plan that vested as follows: (i) 175,747 shares became exercisable when the Issuer's common stock price closed at $22 per share (or above) for 40 consecutive trading days before the third anniversary of the Grant Date (the "Performance End Date"); (ii) 181,160 shares became exercisable when the Issuer's common stock price closed at $25 per share (or above) for 40 consecutive trading days before the Performance End Date; and (iii) 193,424 shares became exercisable when the Issuer's common stock price closed at $29 per share (or above) for 40 consecutive trading days before the Performance End Date, in each case subject to the reporting person's Employment Agreement and provided that no option shares vested prior to the one-year anniversary of the Grant Date. F3 · derivative.expiration_date: Option to purchase shares of common stock granted on July 12, 2020 ("Grant Date") under the Plan that vested as follows: (i) 175,747 shares became exercisable when the Issuer's common stock price closed at $22 per share (or above) for 40 consecutive trading days before the third anniversary of the Grant Date (the "Performance End Date"); (ii) 181,160 shares became exercisable when the Issuer's common stock price closed at $25 per share (or above) for 40 consecutive trading days before the Performance End Date; and (iii) 193,424 shares became exercisable when the Issuer's common stock price closed at $29 per share (or above) for 40 consecutive trading days before the Performance End Date, in each case subject to the reporting person's Employment Agreement and provided that no option shares vested prior to the one-year anniversary of the Grant Date. Read SEC document
August 30, 2021 Filed Aug 31, 2021 23:49 UTC	Pediatrix Medical Group, Inc. MD · Entity 4451	SaleCommon Stock	95,000	$35.09	$3,333,550.00	Disclosure SEC source: 0001209191-21-054168 · doc4.xml · nonDerivative · entry 2 ORDAN MARK S · CIK 0001208541 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 208,425 F2 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions with prices ranging from $34.965 to $35.235 for a weighted average sales price of $35.09. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
August 30, 2021 Filed Aug 31, 2021 23:49 UTC	Pediatrix Medical Group, Inc. MD · Entity 4451	Exercise / conversionCommon Stock	95,000	$17.65	$1,676,750.00	Disclosure SEC source: 0001209191-21-054168 · doc4.xml · nonDerivative · entry 1 ORDAN MARK S · CIK 0001208541 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 303,425 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares acquired upon exercise of Stock Options granted pursuant to Issuer's Amended and Restated 2008 Incentive Compensation Plan (the "Plan"). Read SEC document
March 01, 2021 Filed Mar 3, 2021 21:41 UTC	Pediatrix Medical Group, Inc. MD · Entity 4451	GrantCommon Stock	71,429	$0.00	$0.00	Disclosure SEC source: 0001209191-21-016899 · doc4.xml · nonDerivative · entry 2 ORDAN MARK S · CIK 0001208541 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 208,425 F2 · kind: Restricted shares granted pursuant to the Issuer's Plan, in connection with an annual equity award. Twenty-five percent (25%) of the restricted shares will vest on March 1, 2022, twenty-five percent (25%) of the restricted shares will vest on March 1, 2023 and fifty percent (50%) of the restricted shares will vest on March 1, 2024. Read SEC document
March 01, 2021 Filed Mar 3, 2021 21:41 UTC	Pediatrix Medical Group, Inc. MD · Entity 4451	GrantCommon Stock	71,429	$0.00	$0.00	Disclosure SEC source: 0001209191-21-016899 · doc4.xml · nonDerivative · entry 1 ORDAN MARK S · CIK 0001208541 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,996 F1 · kind: Restricted shares granted pursuant to the Issuer's Amended and Restated 2008 Incentive Compensation Plan (the "Plan"), in connection with an annual equity award. The number of shares being reported represents the "target" number of restricted shares and does not include the right of the reporting person to receive up to 35,715 additional shares based on the achievement of certain performance-based criteria for the twelve months ending December 31, 2021. The actual number of shares earned could be less than or greater than the target number, depending on the level of performance achieved, and all of the restricted shares granted are subject to forfeiture if minimum levels of performance are not met. Any restricted shares earned will not vest any earlier than in three installments of twenty-five percent (25%) on March 1, 2022, twenty-five percent (25%) on March 1, 2023 and fifty percent (50%) on March 1, 2024, subject to the terms of the Plan. Read SEC document
January 04, 2021 Filed Jan 6, 2021 21:35 UTC	FEDERAL REALTY INVESTMENT TRUST FRT · Entity 3517	GrantCommon Shares of Beneficial Interest	1,410	$0.00	$0.00	Disclosure SEC source: 0000034903-21-000007 · wf-form4_160996889899069.xml · nonDerivative · entry 1 ORDAN MARK S · CIK 0001208541 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,222 Read SEC document
July 13, 2020 Filed Jul 14, 2020 20:49 UTC	VEREIT, Inc. VER · Entity 134043	GrantCommon Stock	1,111	$7.28	$8,082.53	Disclosure SEC source: 0001507385-20-000130 · wf-form4_159475977784440.xml · nonDerivative · entry 2 ORDAN MARK S · CIK 0001208541 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,206 F3 · shares: Reflects deferred stock units granted on July 13, 2020 in lieu of dividends pursuant to the director's deferral election. Such deferred stock units will be settled in common stock in connection with the Reporting Person's separation of service from the Issuer. F4 · price: Reflects the average of the closing sale price as reported on the New York Stock Exchange on January 15, 2020 and April 15, 2020. Read SEC document
July 13, 2020 Filed Jul 14, 2020 20:49 UTC	VEREIT, Inc. VER · Entity 134043	GrantCommon Stock	544	$6.17	$3,356.48	Disclosure SEC source: 0001507385-20-000130 · wf-form4_159475977784440.xml · nonDerivative · entry 1 ORDAN MARK S · CIK 0001208541 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,095 F1 · shares: Reflects deferred stock units granted on July 13, 2020, in lieu of director fees pursuant to the director's deferral election. Such deferred stock units will be settled in common stock in connection with the Reporting Person's separation of service from the Issuer. F2 · price: Reflects the closing sale price of the Issuer's common stock as reported on the New York Stock Exchange on July 13, 2020. Read SEC document
July 12, 2020 Filed Jul 15, 2020 00:23 UTC	Pediatrix Medical Group, Inc. MD · Entity 4451	GrantEmployee Stock Option (right to buy) · Derivative	550,331	$0.00 Strike: $17.65	$0.00	Disclosure SEC source: 0001209191-20-042455 · doc4.xml · derivative · entry 3 ORDAN MARK S · CIK 0001208541 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 550,331 Underlying: Common Stock · 550,331 shares Expires 2023-10-10 F3 · derivative.exercise_date: Option to purchase shares of common stock awarded under the Plan that vests as follows: (i) 175,747 shares are exercisable if and when the Issuer's common stock price closes at $22 per share (or above) for any 40 consecutive trading days before the third anniversary of the grant date ("Performance End Date"); (ii) 181,160 shares are exercisable if and when Issuer's common stock price closes at $25 per share (or above) for any 40 consecutive trading days before Performance End Date; and (iii) 193,424 shares are exercisable if and when Issuer's common stock price closes at $29 per share (or above) for any 40 consecutive trading days before Performance End Date in each case subject to the Reporting Person's Employment Agreement; provided, that no option shares will vest prior to the one-year anniversary of the grant date. F3 · derivative.expiration_date: Option to purchase shares of common stock awarded under the Plan that vests as follows: (i) 175,747 shares are exercisable if and when the Issuer's common stock price closes at $22 per share (or above) for any 40 consecutive trading days before the third anniversary of the grant date ("Performance End Date"); (ii) 181,160 shares are exercisable if and when Issuer's common stock price closes at $25 per share (or above) for any 40 consecutive trading days before Performance End Date; and (iii) 193,424 shares are exercisable if and when Issuer's common stock price closes at $29 per share (or above) for any 40 consecutive trading days before Performance End Date in each case subject to the Reporting Person's Employment Agreement; provided, that no option shares will vest prior to the one-year anniversary of the grant date. Read SEC document
July 12, 2020 Filed Jul 15, 2020 00:23 UTC	Pediatrix Medical Group, Inc. MD · Entity 4451	Tax withholdingCommon Stock	47,747	$17.65	$842,734.55	Disclosure SEC source: 0001209191-20-042455 · doc4.xml · nonDerivative · entry 2 ORDAN MARK S · CIK 0001208541 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,567 F2 · shares: Represents shares withheld for the payment of taxes upon the vesting of shares of restricted stock reported in Table I. Read SEC document
July 12, 2020 Filed Jul 15, 2020 00:23 UTC	Pediatrix Medical Group, Inc. MD · Entity 4451	GrantCommon Stock	113,314	$0.00	$0.00	Disclosure SEC source: 0001209191-20-042455 · doc4.xml · nonDerivative · entry 1 ORDAN MARK S · CIK 0001208541 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,314 F1 · shares: Represents shares of restricted stock awarded to the Reporting Person under the Issuer's Amended and Restated 2008 Incentive Compensation Plan (the "Plan") in connection with his appointment as Chief Executive Officer of the Issuer. Such shares are fully vested on the date of grant but may not be transferred until the earlier of (i) the fifth anniversary of the grant date and (ii) the date of the closing of a "Change in Control" of the Issuer (as defined in the Reporting Person's Employment Agreement), subject to certain exceptions. Read SEC document
June 30, 2020 Filed Jul 2, 2020 20:52 UTC	VEREIT, Inc. VER · Entity 134043	GrantCommon Stock	3,694	$6.43	$23,752.42	Disclosure SEC source: 0001507385-20-000123 · wf-form4_159372307612982.xml · nonDerivative · entry 1 ORDAN MARK S · CIK 0001208541 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,551 F1 · shares: Reflects deferred stock units granted on June 30, 2020, in lieu of director fees pursuant to the director's deferral election. Such deferred stock units will be settled in common stock upon the earlier of the Reporting Person's separation of service from the Issuer, death or a change in control of the Issuer. F2 · price: Reflects the closing sale price of the Issuer's common stock as reported on the New York Stock Exchange on June 30, 2020. Read SEC document
May 21, 2020 Filed May 26, 2020 21:17 UTC	VEREIT, Inc. VER · Entity 134043	GrantCommon Stock	23,541	$5.31	$125,002.71	Disclosure SEC source: 0001507385-20-000100 · wf-form4_159052783240504.xml · nonDerivative · entry 1 ORDAN MARK S · CIK 0001208541 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,857 F1 · shares: Reflects deferred stock units granted on May 21, 2020 in respect of the annual equity retainer due to the Reporting Person, for the Reporting Person's service as an independent director. Pursuant to the director's deferral election, such deferred stock units will be settled in common stock upon the earlier of the Reporting Person's separation from service from the Issuer, death or a change in control of the Issuer. F2 · price: Reflects the closing sale price of the Issuer's common stock as reported on the New York Stock Exchange on May 21, 2020. Read SEC document
March 31, 2020 Filed Apr 2, 2020 20:44 UTC	VEREIT, Inc. VER · Entity 134043	GrantCommon Stock	4,857	$4.89	$23,750.73	Disclosure SEC source: 0001507385-20-000058 · wf-form4_158586024391970.xml · nonDerivative · entry 1 ORDAN MARK S · CIK 0001208541 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,316 F1 · shares: Reflects deferred stock units granted on March 31, 2020, in lieu of director fees pursuant to the director's deferral election. Such deferred stock units will be settled in common stock upon the earlier of the Reporting Person's separation of service from the Issuer, death or a change in control of the Issuer. F2 · price: Reflects the closing sale price of the Issuer's common stock as reported on the New York Stock Exchange on March 31, 2020. Read SEC document
January 02, 2020 Filed Jan 3, 2020 22:12 UTC	FEDERAL REALTY INVESTMENT TRUST FRT · Entity 3517	GrantCommon shares of beneficial interest	812	$0.00	$0.00	Disclosure SEC source: 0001208541-20-000001 · edgar.xml · nonDerivative · entry 1 ORDAN MARK S · CIK 0001208541 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 812 Read SEC document
December 31, 2019 Filed Jan 3, 2020 21:31 UTC	VEREIT, Inc. VER · Entity 134043	GrantCommon Stock	2,895	$9.24	$26,749.80	Disclosure SEC source: 0001507385-20-000006 · wf-form4_157808709262227.xml · nonDerivative · entry 1 ORDAN MARK S · CIK 0001208541 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,459 F1 · shares: Reflects deferred stock units granted on December 31, 2019, in lieu of director fees pursuant to the director's deferral election. Such deferred stock units will be settled in common stock upon the earlier of the Reporting Person's separation of service from the Issuer, death or a change in control of the Issuer. F2 · price: Reflects the closing sale price of the Issuer's common stock as reported on the New York Stock Exchange on December 31, 2019. Read SEC document
October 15, 2019 Filed Oct 17, 2019 21:01 UTC	VEREIT, Inc. VER · Entity 134043	GrantCommon Stock	1,195	$8.70	$10,400.09	Disclosure SEC source: 0001507385-19-000151 · wf-form4_157134605386028.xml · nonDerivative · entry 1 ORDAN MARK S · CIK 0001208541 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,564 F1 · shares: Reflects deferred stock units granted on October 15, 2019 in lieu of dividends pursuant to the director's deferral election. Such deferred stock units will be settled in common stock upon the earlier of the Reporting Person's separation of service from the Issuer, death or a change in control of the Issuer. F2 · price: Reflects the average of the closing sale price as reported on the New York Stock Exchange on January 15, 2019, April 15, 2019, July 15, 2019, and October 15, 2019. Read SEC document
September 30, 2019 Filed Oct 2, 2019 20:36 UTC	VEREIT, Inc. VER · Entity 134043	GrantCommon Stock	2,582	$9.78	$25,251.96	Disclosure SEC source: 0001507385-19-000135 · wf-form4_157004854791360.xml · nonDerivative · entry 1 ORDAN MARK S · CIK 0001208541 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,369 F1 · shares: Reflects deferred stock units granted on September 30, 2019, in lieu of director fees pursuant to the director's deferral election. Such deferred stock units will be settled in common stock upon the earlier of the Reporting Person's separation of service from the Issuer, death or a change in control of the Issuer. F2 · price: Reflects the closing sale price of the Issuer's common stock as reported on the New York Stock Exchange on September 30, 2019. Read SEC document
June 28, 2019 Filed Jul 2, 2019 20:39 UTC	VEREIT, Inc. VER · Entity 134043	GrantCommon Stock	2,636	$9.01	$23,750.36	Disclosure SEC source: 0001507385-19-000114 · wf-form4_156209994212821.xml · nonDerivative · entry 1 ORDAN MARK S · CIK 0001208541 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,787 F1 · shares: Reflects deferred stock units granted on June 28, 2019, in lieu of director fees pursuant to the director's deferral election. Such deferred stock units will be settled in common stock upon the earlier of the Reporting Person's separation of service from the Issuer, death or a change in control of the Issuer. F2 · price: Reflects the closing sale price of the Issuer's common stock as reported on the New York Stock Exchange on June 28, 2019. Read SEC document
May 06, 2019 Filed May 8, 2019 20:35 UTC	VEREIT, Inc. VER · Entity 134043	GrantCommon Stock	14,970	$8.35	$124,999.50	Disclosure SEC source: 0001507385-19-000104 · wf-form4_155734770936834.xml · nonDerivative · entry 1 ORDAN MARK S · CIK 0001208541 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,151 F1 · shares: Reflects deferred stock units awarded May 6, 2019 in respect of the annual equity retainer due to the Reporting Person, for the Reporting Person's service as an independent director. Such deferred stock units will be settled in common stock upon the earlier of three years from the date of grant, the Reporting Person's death and the Reporting Person's separation from service from the Issuer. F2 · price: Reflects the closing sale price of the Issuer's common stock as reported on the New York Stock Exchange on May 6, 2019. Read SEC document
March 29, 2019 Filed Apr 2, 2019 20:29 UTC	VEREIT, Inc. VER · Entity 134043	GrantCommon Stock	2,838	$8.37	$23,754.06	Disclosure SEC source: 0001507385-19-000064 · wf-form4_155423693184932.xml · nonDerivative · entry 1 ORDAN MARK S · CIK 0001208541 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,181 F1 · shares: Reflects deferred stock units granted on March 29, 2019, in lieu of director fees pursuant to the director's deferral election. Such deferred stock units will be settled in common stock upon the earlier of the Reporting Person's separation of service from the Issuer, death or a change in control of the Issuer. F2 · price: Reflects the closing sale price of the Issuer's common stock as reported on the New York Stock Exchange on March 29, 2019. Read SEC document
December 31, 2018 Filed Jan 3, 2019 21:31 UTC	VEREIT, Inc. VER · Entity 134043	GrantCommon Stock	3,322	$7.15	$23,752.30	Disclosure SEC source: 0001507385-19-000004 · wf-form4_154655105912584.xml · nonDerivative · entry 1 ORDAN MARK S · CIK 0001208541 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,343 F1 · shares: Reflects deferred stock units granted on December 31, 2018, in lieu of director fees pursuant to the director's deferral election. Such deferred stock units will be settled in common stock upon the earlier of the Reporting Person's separation of service from the Issuer, death or a change in control of the Issuer. F2 · price: Reflects the closing sale price of the Issuer's common stock as reported on the New York Stock Exchange on December 31, 2018. Read SEC document
December 07, 2018 Filed Dec 7, 2018 21:30 UTC	Forest City Realty Trust, Inc. FCEA · Entity 161862	Disposition to issuerClass A Common Stock	5,432	Not disclosed	Not disclosed	Disclosure SEC source: 0001208541-18-000008 · edgar.xml · nonDerivative · entry 1 ORDAN MARK S · CIK 0001208541 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · kind: Pursuant to a Merger Agreement dated 7/30/2018, among issuer, Antlia Holdings, LLC and Antlia Merger Sub Inc. (the "Merger Agreement"), at the effective time of the Merger, as contemplated in the Merger Agreement (the "Effective Time"), the restricted shares, outstanding immediately prior to the Effective Time automatically vested and entitled the holder to receive a cash payment of $25.35 per share (the "Merger Consideration") without interest and less any applicable tax withholdings. F2 · price: Pursuant to a Merger Agreement dated 7/30/2018, among issuer, Antlia Holdings, LLC and Antlia Merger Sub Inc. (the "Merger Agreement"), at the effective time of the Merger, as contemplated in the Merger Agreement (the "Effective Time"), the restricted shares, outstanding immediately prior to the Effective Time automatically vested and entitled the holder to receive a cash payment of $25.35 per share (the "Merger Consideration") without interest and less any applicable tax withholdings. F1 · ownership.direct: Restricted Stock Grant pursuant to Forest City Realty Trust, Inc. 1994 Stock Plan - 100% vest on 6/20/2019. Read SEC document
October 15, 2018 Filed Oct 17, 2018 20:27 UTC	VEREIT, Inc. VER · Entity 134043	GrantCommon Stock	439	$7.18	$3,153.34	Disclosure SEC source: 0001507385-18-000139 · wf-form4_153980803251395.xml · nonDerivative · entry 1 ORDAN MARK S · CIK 0001208541 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,021 F1 · shares: Reflects deferred stock units granted on October 15, 2018 in lieu of dividends pursuant to the director's deferral election. Such deferred stock units will be settled in common stock upon the earlier of the Reporting Person's separation of service from the Issuer, death or a change in control of the Issuer. F2 · price: Reflects the average of the closing sale price as reported on the New York Stock Exchange on January 16, 2018, April 16, 2018, July 16, 2018, and October 15, 2018. Read SEC document
September 28, 2018 Filed Oct 2, 2018 20:34 UTC	VEREIT, Inc. VER · Entity 134043	GrantCommon Stock	3,271	$7.26	$23,747.46	Disclosure SEC source: 0001507385-18-000133 · wf-form4_153851242754777.xml · nonDerivative · entry 1 ORDAN MARK S · CIK 0001208541 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,582 F1 · shares: Reflects deferred stock units granted on September 28, 2018, in lieu of director fees pursuant to the director's deferral election. Such deferred stock units will be settled in common stock upon the earlier of the Reporting Person's separation of service from the Issuer, death or a change in control of the Issuer. F2 · price: Reflects the closing sale price of the Issuer's common stock as reported on the New York Stock Exchange on September 28, 2018. Read SEC document
July 26, 2018 Filed Jul 27, 2018 17:03 UTC	QUALITY CARE PROPERTIES, INC. QCP · Entity 164714	Disposition to issuerRestricted Stock Unit · Derivative	203,804	Not disclosed Strike: $0.00	Not disclosed	Disclosure SEC source: 0001104659-18-047758 · a4.xml · derivative · entry 5 ORDAN MARK S · CIK 0001208541 · Director · Director, Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 203,804 shares Expires 2019-11-29 F6 · derivative.exercise_price: Each restricted stock unit represents the right to receive, at settlement, one share of common stock of QCP. F7 · kind: Upon the closing of the Merger, each outstanding QCP restricted stock unit award fully vested and was converted into the right to receive $20.75 in respect of each share underlying the restricted stock unit award. F7 · price: Upon the closing of the Merger, each outstanding QCP restricted stock unit award fully vested and was converted into the right to receive $20.75 in respect of each share underlying the restricted stock unit award. F7 · derivative.exercise_date: Upon the closing of the Merger, each outstanding QCP restricted stock unit award fully vested and was converted into the right to receive $20.75 in respect of each share underlying the restricted stock unit award. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.